Owen Siggs

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.

Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup

19.05.2025 12:15 — 👍 15    🔁 6    💬 2    📌 1

Very excited to share our preprint led by M. Levin @skoyama.bsky.social J. Woerner & with S. Damrauer assessing genome-wide pleiotropy of >1,000 clinical traits across ~1.7M individuals with nearly 30K locus-trait associations!
www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social

23.04.2025 11:35 — 👍 45    🔁 27    💬 3    📌 2

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer | NEJM The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified...

A high polygenic risk score (PRS) for screening prostate cancer was superior to a PSA test or MRI for detecting clinically significant disease (Gleason ≥7). A big step forward for supporting utility of PRS @nejm.org
www.nejm.org/doi/full/10....

09.04.2025 21:24 — 👍 172    🔁 44    💬 2    📌 3

Well done Laura! 🥂

06.12.2024 11:06 — 👍 1    🔁 0    💬 0    📌 0

Interview with Daniel MacArthur This is an interview with Daniel MacArthur, whom I first met when he was at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard in Boston.

I chatted to @stuartbuck.bsky.social about scientific funding in the US and Australia, organisational incentives, institutional senescence, and the joy of seeing other researchers doing clever things with data you released: goodscience.substack.com/p/interview-...

03.12.2024 22:32 — 👍 30    🔁 7    💬 3    📌 0